​

Longeveron Stock (NASDAQ:LGVN)

ForecastRevenueOwnershipFinancialsChartTranscripts
Longeveron by TradingView

Previous Close

$0.94

52W Range

$0.47 - $1.80

50D Avg

$0.86

200D Avg

$0.82

Market Cap

$20.97M

Avg Vol (3M)

$5.68M

Beta

-0.19

Div Yield

-

LGVN Company Profile

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

25

IPO Date

Feb 12, 2021

Website

LGVN Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceMar 21
ClinicalTrialRevenueMember$165.00K
AlzheimersAssociationGrantMember$170.00K
MarylandTEDCOGrantMember$41.00K

Fiscal year ends in Dec 25 | Currency in USD

LGVN Financial Summary

Dec 25Dec 24Dec 23
Revenue$1.20M$2.39M$709.00K
Operating Income$-23.29M$-16.52M$-21.03M
Net Income$-22.70M$-15.97M$-21.41M
EBITDA$-23.29M$-15.56M$-20.08M
Basic EPS$-1.29$-1.07$-10.22
Diluted EPS$-1.29$-1.07$-10.22

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 25Mar 17, 26 | 12:00 AM
Q3 25Nov 04, 25 | 4:30 PM
Q2 25Aug 13, 25 | 4:30 PM

Peer Comparison

TickerCompany
DAREDaré Bioscience, Inc.
ASBPAspire Biopharma Holdings, Inc.
PCSAProcessa Pharmaceuticals, Inc.
ATHAAthira Pharma, Inc.
CRISCuris, Inc.
PULMPulmatrix, Inc.
LPTXLeap Therapeutics, Inc.
CTXRCitius Pharmaceuticals, Inc.
FBLGFibroBiologics, Inc. Common Stock
PALIPalisade Bio, Inc.